Biopharma's Default Position: Drug Stocks Hold Up Against US Downgrade
This article was originally published in RPM Report
Executive Summary
Economists are fretting that the US may be heading into a “lost decade” of stagnation. Will those fears help Big Pharma investors finally end a lost decade of their own?